Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 28:12:1756284818821266.
doi: 10.1177/1756284818821266. eCollection 2019.

Golimumab in the treatment of ulcerative colitis

Georgina Cunningham  1 , Mark A Samaan  1 , Peter M Irving  2
Affiliations
Review

Golimumab in the treatment of ulcerative colitis

Georgina Cunningham et al. Therap Adv Gastroenterol. .

Abstract

Golimumab was approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of moderate-to-severe ulcerative colitis in 2013 and was the third antitumour-necrosis-factor therapy after adalimumab and infliximab licensed for this indication. However, given it is the most recent of these drugs to become available, evidence regarding its optimal use and its positioning in relation to other biological therapies is only now emerging. In this article, we review the efficacy, effectiveness and safety of golimumab both in the setting of clinical trials and in 'real world' observational studies. We also explore the limited data available regarding the possible role of therapeutic-drug monitoring and dose flexibility.

Keywords: Simponi; golimumab; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: GC: none. MAS: advisory fees: Takeda, Janssen; lecture fees: Takeda, MSD, Janssen, Dr Falk Pharma. PMI: advisory fees: Abbvie, Warner Chilcott, Takeda, MSD, Vifor Pharma, Pharmacosmos, Topivert, Genentech, Hospira, Samsung Bioepis; lecture fees: Abbvie, Warner Chilcott, Ferring, Dr Falk Pharma, Takeda, MSD, Johnson and Johnson, Shire.

References

    1. Shealy DJ, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs 2010; 2: 428–439. - PMC - PubMed
    1. Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med 2014; 160: 704–711. - PubMed
    1. Singh S, Fumery M, Sandborn WJ, et al. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 162–175. - PubMed
    1. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 85–95. - PubMed
    1. Rutgeerts P, Feagan BG, Marano CW, et al. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther 2015; 42: 504–514. - PMC - PubMed

LinkOut - more resources